Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 4/20 | 0.47 |
| ▸ | USP8 | P40818 | 4/20 | 0.47 |
| ▸ | ACLY | P53396 | 3/20 | 0.46 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GPR27 | Q9NS67 | 4/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24268135 | 0.89 | USP2 (0.47) | USP2USP8ACLYUSP36KDM1A | |
| SCHEMBL23879544 | 0.88 | KDM1A (0.49) | USP2USP8ACLYUSP36KDM1A | |
| SCHEMBL23879578 | 0.87 | USP2 (0.46) | USP2USP8ACLYUSP36KDM1A | |
| SCHEMBL23879622 | 0.87 | USP2 (0.46) | USP2USP8ACLYUSP36KDM1A | |
| SCHEMBL23879530 | 0.83 | ACLY (0.52) | USP2USP8ACLYUSP36KDM1A | |
| SCHEMBL23879624 | 0.83 | USP2 (0.44) | USP2USP8ACLYUSP36KDM1A | |
| SCHEMBL23879531 | 0.83 | MCL1 (0.40) | USP2USP8ACLYUSP36KCNA5 | |
| SCHEMBL23879648 | 0.81 | USP2 (0.42) | USP2USP8ACLYUSP36KDM1A | |
| SCHEMBL24268039 | 0.81 | RAB9A (0.43) | USP2USP8ACLYUSP36LMNA | |
| SCHEMBL23879626 | 0.79 | USP2 (0.48) | USP2USP8ACLYUSP36KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | USP2 3178/4885USP8 3142/4885ACLY 2228/4885 |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | USP2 3178/4885USP8 3142/4885ACLY 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.